- Home
- OBIO vs KLRS Comparison
OBIO vs KLRS Comparison
Compare OBIO & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OBIO
- KLRS
- Stock Information
- Founded
- OBIO 2017
- KLRS 2019
- Country
- OBIO United States
- KLRS United States
- Employees
- OBIO N/A
- KLRS N/A
- Industry
- OBIO Medicinal Chemicals and Botanical Products
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OBIO Health Care
- KLRS Health Care
- Exchange
- OBIO Nasdaq
- KLRS Nasdaq
- Market Cap
- OBIO 151.3M
- KLRS 129.0M
- IPO Year
- OBIO N/A
- KLRS N/A
- Fundamental
- Price
- OBIO $2.85
- KLRS $2.90
- Analyst Decision
- OBIO Strong Buy
- KLRS Buy
- Analyst Count
- OBIO 5
- KLRS 1
- Target Price
- OBIO $14.20
- KLRS N/A
- AVG Volume (30 Days)
- OBIO 193.1K
- KLRS 52.4K
- Earning Date
- OBIO 05-12-2025
- KLRS 05-14-2025
- Dividend Yield
- OBIO N/A
- KLRS N/A
- EPS Growth
- OBIO N/A
- KLRS N/A
- EPS
- OBIO N/A
- KLRS N/A
- Revenue
- OBIO $2,886,000.00
- KLRS N/A
- Revenue This Year
- OBIO $21.38
- KLRS N/A
- Revenue Next Year
- OBIO $31.89
- KLRS N/A
- P/E Ratio
- OBIO N/A
- KLRS N/A
- Revenue Growth
- OBIO 30.23
- KLRS N/A
- 52 Week Low
- OBIO $2.37
- KLRS $2.65
- 52 Week High
- OBIO $8.87
- KLRS $24.15
- Technical
- Relative Strength Index (RSI)
- OBIO 49.08
- KLRS N/A
- Support Level
- OBIO $2.61
- KLRS N/A
- Resistance Level
- OBIO $3.02
- KLRS N/A
- Average True Range (ATR)
- OBIO 0.18
- KLRS 0.00
- MACD
- OBIO 0.04
- KLRS 0.00
- Stochastic Oscillator
- OBIO 60.19
- KLRS 0.00
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing therapeutics. Kalaris is developing TH103, a novel, clinical stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body native, highest affinity VEGF receptor 1.